Want to see AU:OCC full AI Analyst Report?
Top Page
Orthocell Ltd
(Sydney:OCC)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.72
▼(-8.21% Downside)
Action:Reiterated
Date:09/06/26
The score is primarily constrained by weak financial quality—large operating losses and ongoing cash burn—despite strong revenue growth. Technicals add further pressure given the stock is trading below major moving averages with negative momentum signals. Valuation is mixed-to-neutral because the negative P/E reflects current losses and dividend information is unavailable.
Positive Factors
Strong revenue scaling
Rapid multi-year revenue expansion indicates growing commercial traction for Orthocell’s regenerative medicine products. Continued top-line growth can broaden operating scale, support market development, and create a foundation for eventual operating leverage if investment spending becomes more efficient.
Negative Factors
Deep ongoing losses
The scale of current losses shows that revenue growth has not yet translated into a sustainable earnings model. Persistent negative margins may require continued investment funding and leave the company exposed if commercial expansion does not deliver sufficient operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue scaling
Rapid multi-year revenue expansion indicates growing commercial traction for Orthocell’s regenerative medicine products. Continued top-line growth can broaden operating scale, support market development, and create a foundation for eventual operating leverage if investment spending becomes more efficient.
Read all positive factors
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$187.95M
Dividend YieldN/A
Average Volume (3M)296.44K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue Growth51.07%
EPS Growth-47.63%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding272,393,700
10 Day Avg. Volume292,130
30 Day Avg. Volume296,440
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)5.55
Price to Sales (P/S)16.74
P/FCF Ratio-13.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.13Price Target Upside44.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$19.60M
Orthocell Ltd Business Overview & Revenue Model
Company Description
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are desig...
How the Company Makes Money
Orthocell makes money primarily through product sales of its commercialised regenerative medicine devices/biologics and related distribution channels, along with other operating income linked to its commercial and development activities. Key reven...
Orthocell Ltd Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.41M | 7.55M | 5.32M | 4.24M | 1.53M |
| Gross Profit | 3.68M | 4.80M | 3.69M | 3.06M | 832.52K |
| EBITDA | -17.52M | -13.43M | -11.68M | -10.34M | -11.52M |
| Net Income | -13.91M | -8.57M | -7.18M | -6.25M | -9.11M |
Balance Sheet | |||||
| Total Assets | 54.81M | 35.24M | 26.62M | 29.61M | 37.90M |
| Cash, Cash Equivalents and Short-Term Investments | 44.15M | 28.62M | 20.61M | 24.82M | 11.02M |
| Total Debt | 1.55M | 576.89K | 689.69K | 562.30K | 507.56K |
| Total Liabilities | 20.40M | 20.67M | 22.08M | 23.46M | 27.99M |
| Stockholders Equity | 34.41M | 14.57M | 4.53M | 6.15M | 9.90M |
Cash Flow | |||||
| Free Cash Flow | -14.43M | -9.04M | -7.45M | 13.96M | -6.80M |
| Operating Cash Flow | -13.32M | -8.68M | -6.51M | 14.59M | -6.26M |
| Investing Cash Flow | -36.97M | -359.06K | -942.02K | -631.56K | -535.02K |
| Financing Cash Flow | 31.12M | 17.05M | 3.24M | -164.61K | 1.49M |
Orthocell Ltd Technical Analysis
Negative
0.78
Price Trends
0.75
Negative
0.75
Negative
0.83
Negative
Market Momentum
>-0.01
Positive
37.87
Neutral
11.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OCC, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.75, and below the 200-day MA of 0.83, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.87 is Neutral, neither overbought nor oversold. The STOCH value of 11.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OCC.
Orthocell Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$2.60B | -31.48 | -10.06% | ― | 555.67% | 49.08% | |
52 Neutral | AU$15.89M | -2.14 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$187.95M | -13.02 | -36.83% | ― | 51.07% | -47.63% | |
43 Neutral | AU$5.14M | -0.96 | -52.04% | ― | 32.22% | -26.53% | |
41 Neutral | AU$3.41M | -0.36 | -607.23% | ― | ― | 13.50% | |
40 Underperform | AU$16.22M | -4.44 | -132.20% | ― | ― | -200.00% |
* Healthcare Sector Average
AU:OCC
Orthocell Ltd
0.69
-0.76
-52.41%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.21
-93.78%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
2.00
-0.82
-29.08%
AU:TRP
Tissue Repair Ltd
0.09
-0.19
-68.52%
AU:CMB
Regeneus Ltd.
0.54
0.04
8.00%
Orthocell Ltd Corporate Events
Orthocell Files 2026 Corporate Governance Appendix with ASX
Aug 31, 2026
Orthocell Limited has lodged its Appendix 4G with the ASX for the year ended 30 June 2026, confirming the location and currency of its corporate governance statement. The filing states that the board has approved the statement, which is available ...
Orthocell posts full-year 2026 results and details progress in regenerative medicine portfolio
Aug 31, 2026
Orthocell Limited, a Perth-based regenerative medicine specialist, develops collagen-based medical devices for dental and orthopaedic tissue reconstruction and autologous cell therapies targeting tendon and cartilage repair. Its key products inclu...
Orthocell to Showcase Regenerative Growth Strategy at Canaccord Conference
Aug 11, 2026
Regenerative medicine specialist Orthocell Ltd, listed on the ASX, develops collagen-based medical devices and autologous cell therapies designed to repair bone, nerve, tendon and cartilage injuries, with products such as Striate+, Remplir and Smr...
Orthocell Targets Global Investors at Canaccord Growth Conference
Aug 10, 2026
Regenerative medicine developer Orthocell Ltd will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston from 11–13 August 2026. Chairman John Van Der Wielen and managing director Paul Anderson plan to meet life scienc...
Orthocell Relocates Registered Office to Murdoch University Campus
Aug 2, 2026
Orthocell Ltd, a Perth-based regenerative medicine company specialising in collagen-based medical devices and autologous cell therapies for bone, soft tissue, nerve and tendon repair, has established its registered office at Murdoch University in ...
Orthocell Issues Cautious Q4 FY26 Investor Presentation Disclaimer
Jul 13, 2026
Orthocell has released a Q4 FY26 investor presentation outlining information intended for potential investors, while emphasising that the document is confidential and does not constitute an offer or solicitation to buy or sell securities. The comp...
Orthocell hits record revenue as Remplir adoption accelerates and global rollout advances
Jul 12, 2026
Orthocell reported record quarterly revenue of $3.8 million and full-year FY2026 revenue of $13.2 million, driven by accelerating adoption of its Remplir nerve repair device and Striate+ worldwide. The company highlighted a three-year trajectory o...
Orthocell to Unveil Quarterly Results and Detail U.S. Rollout of Remplir
Jul 5, 2026
Orthocell Ltd has scheduled the release of its quarterly results for 13 July 2026 and will host an investor webinar on 14 July 2026 to present its financial performance and provide an operational update. Senior executives, including the chair, CEO...
Orthocell Expands Humanitarian Use of Remplir Nerve Repair Device in Ukraine
Jun 29, 2026
Orthocell has expanded the humanitarian deployment of its Remplir nerve repair device in Ukraine, as surgeons report strong clinical utility in treating complex battlefield and civilian trauma, including severe peripheral nerve injuries from amput...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.